Phase II Optimization, Open-Label Clinical Trial of Zalypsis® (PM00104) in Relapsed/Refractory Multiple Myeloma Patients

被引：0
|
作者：
Ocio, Enrique M. [1 ]
De La Rubia, Javier [2 ]
Oriol-Rocafiguera, Albert [3 ]
Blade, Joan [4 ]
Rodriguez, Jose [5 ]
Coronado, Cinthya [5 ]
Martin Sanchez, Jesus [6 ]
Isabel Teruel, Ana [7 ]
Hernandez-Maraver, Dolores [8 ]
Prosper, Felipe [9 ]
San-Miguel, Jesus. F.
机构：
[1] Hosp Univ Salamanca, Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain
[2] Hosp Univ La Fe, Valencia, Spain
[3] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
[4] Hosp Clin Barcelona, Barcelona, Spain
[5] PharmaMar, Madrid, Spain
[6] Hosp Univ Virgen del Rocio, Seville, Spain
[7] Hosp Clin Univ Valencia, Valencia, Spain
[8] Hosp La Paz, Madrid, Spain
[9] Univ Navarra Clin, Pamplona, Spain
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.4041.4041
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4041
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF BORTEZOMIB AND DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Jakubowiak, A.
    Offidani, M.
    Pegourie, B.
    De La Rubia, J.
    Garderet, L.
    Laribi, K.
    Bosi, A.
    Marasca, R.
    Laubach, J.
    Mohrbacher, A.
    Carella, A. M.
    Singhal, A. K.
    Tsao, L. C.
    Lynch, M.
    Bleickardt, E.
    Jou, Y. M.
    Palumbo, A.
    HAEMATOLOGICA, 2015, 100 : 2 - 2
  • [22] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
    Richardson, Paul G.
    Oriol, Albert
    Beksac, Meral
    Liberati, Anna Marina
    Galli, Monica
    Schjesvold, Fredrik
    Lindsay, Jindriska
    Weisel, Katja
    White, Darrell
    Facon, Thierry
    Miguel, Jesus Son
    Sunami, Kazutaka
    O'Gorman, Peter
    Sonneveld, Pieter
    Robak, Pawel
    Semochkin, Sergey
    Schey, Steve
    Yu, Xin
    Doerr, Thomas
    Bensmaine, Amine
    Biyukov, Tsvetan
    Peluso, Teresa
    Zaki, Mohamed
    Anderson, Kenneth
    Dimopoulos, Meletios
    LANCET ONCOLOGY, 2019, 20 (06): : 781 - 794
  • [23] A Phase 3 randomized, open-label trial of selinexor, pomalidomide, and dexamethasone versus elotuzumab, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma
    Weisel, Katja
    Bentur, Ohad
    Van Domelen, Dane
    Boccadoro, Mario
    Sonneveld, Pieter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S216 - S217
  • [24] PHASE I, OPEN-LABEL TRIAL OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Zhang, W.
    Zhao, W.
    Liu, J.
    He, A.
    Chen, Y.
    Cao, X.
    Yang, N.
    Wang, B.
    Zhang, P.
    Zhang, Y.
    Wang, F.
    Lei, B.
    Gu, L.
    Yang, Y.
    Bai, J.
    Zhang, R.
    Wang, X.
    Ma, X.
    Wang, J.
    Wang, J.
    Wei, L.
    Zhang, J.
    Zang, X.
    Zhuang, Q.
    Fan, F. X.
    HAEMATOLOGICA, 2017, 102 : 2 - 3
  • [25] Update On the Phase IIb, Open-Label Study of Vorinostat in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma.
    Siegel, David
    Jagannath, Sundar
    Lonial, Sagar
    Dimopoulos, Meletios A.
    Graef, Thorsten
    Pietrangelo, Dina
    Lupinacci, Lisa
    Reiser, David
    Rizvi, Syed
    Anderson, Kenneth C.
    BLOOD, 2009, 114 (22) : 1497 - 1497
  • [26] Phase 2, open-label study of venetoclax in combination with carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Bueno, Orlando
    Xu, Tu
    Cordero, Jaclyn
    Morris, Lura
    Ross, Jeremy
    Freise, Kevin
    Munasinghe, Wijith
    Leverson, Joel
    Mudd, Sarah
    Verdugo, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [27] Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
    Mateos, Maria-Victoria
    Blacklock, Hilary
    Schjesvold, Fredrik
    Oriol, Albert
    Simpson, David
    George, Anupkumar
    Goldschmidt, Hartmut
    Larocca, Alessandra
    Chanan-Khan, Asher
    Sherbenou, Daniel
    Avivi, Irit
    Benyamini, Noam
    Iida, Shinsuke
    Matsumoto, Morio
    Suzuki, Kenshi
    Ribrag, Vincent
    Usmani, Saad Z.
    Jagannath, Sundar
    Ocio, Enrique M.
    Rodriguez-Otero, Paula
    San Miguel, Jesus
    Kher, Uma
    Farooqui, Mohammed
    Liao, Jason
    Marinello, Patricia
    Lonial, Sagar
    LANCET HAEMATOLOGY, 2019, 6 (09): : E459 - E469
  • [28] Phase 1 open-label study of panobinostat, lenalidomide, bortezomib plus dexamethasone in relapsed and relapsed/refractory multiple myeloma
    Laubach, Jacob P.
    Tuchman, Sascha A.
    Rosenblatt, Jacalyn M.
    Mitsiades, Constantine S.
    Colson, Kathleen
    Masone, Kelly
    Warren, Diane
    Redd, Robert A.
    Grayson, Dena
    Richardson, Paul G.
    BLOOD CANCER JOURNAL, 2021, 11 (02)
  • [29] A multicenter, open-label phase II study of recombinant CPT (Circularly Permuted TRAIL) plus thalidomide in patients with relapsed and refractory multiple myeloma
    Geng, Chuanying
    Hou, Jian
    Zhao, Yaozhong
    Ke, Xiaoyan
    Wang, Zhao
    Qiu, Lugui
    Xi, Hao
    Wang, Fuxu
    Wei, Na
    Liu, Yan
    Yang, Shifang
    Wei, Peng
    Zheng, Xiangjun
    Huang, Zhongxia
    Zhu, Bing
    Chen, Wen-Ming
    AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (11) : 1037 - 1042
  • [30] First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours
    Yap, T. A.
    Cortes-Funes, H.
    Shaw, H.
    Rodriguez, R.
    Olmos, D.
    Lal, R.
    Fong, P. C.
    Tan, D. S.
    Harris, D.
    Capdevila, J.
    Coronado, C.
    Alfaro, V.
    Soto-Matos, A.
    Fernandez-Teruel, C.
    Siguero, M.
    Tabernero, J. M.
    Paz-Ares, L.
    de Bono, J. S.
    Lopez-Martin, J. A.
    BRITISH JOURNAL OF CANCER, 2012, 106 (08) : 1379 - 1385
12345